APERTO-紫杉醇药物洗脱球囊血管成形术与标准经皮腔内血管成形术治疗功能不良血液透析移植物和自体动静脉内瘘的多中心随机对照试验
这项多中心随机对照试验将103例因流出静脉狭窄导致透析通路功能不良的患者按1:1随机分入APERTO-紫杉醇药物涂层球囊组(51例)或标准经皮腔内血管成形术组,主要终点为治疗至透析通路功能不良的时间。结果显示两组器械相关并发症均未发生,1年无需再干预的功能性透析通路比例分别为19.6%和9.6%(p=0.612),差异无统计学意义。
要点
- APERTO-紫杉醇药物涂层球囊是处理功能不良血液透析通路的安全球囊导管。
- 与标准经皮腔内血管成形术相比,APERTO药物涂层球囊未显示更长的通路功能维持时间。
- 在自体动静脉内瘘新发病变中,APERTO药物涂层球囊显示出非显著获益(25% vs 11%,p=0.953)。
核心结论
- APERTO-紫杉醇药物涂层球囊是处理功能不良血液透析通路的安全球囊导管,但与经皮腔内血管成形术相比,未能证明使用APERTO-紫杉醇药物涂层球囊可在血管内治疗指数狭窄后获得更长的充分血液透析回路功能维持时间。
研究设计与样本
- 多中心随机对照试验,连续纳入因流出静脉狭窄导致透析通路功能不良的患者,按1:1随机分入APERTO-紫杉醇药物涂层球囊组(研究组)或标准经皮腔内血管成形术组(对照组),共103例(研究组n=51)。
- 纳入患者中自体动静脉内瘘79例、新发病变33例、前臂病变60例,多数为男性,平均年龄69.8岁。
主要发现
- 任何纳入患者均未发生器械相关并发症。
- 术后1年无需再干预的功能性血液透析通路在紫杉醇药物涂层球囊组为10例(19.6%),经皮腔内血管成形术组为5例(9.6%)(p=0.612)。
- 在自体动静脉内瘘新发病变中,紫杉醇药物涂层球囊组5例(25%)对比经皮腔内血管成形术组1例(11%),差异无统计学意义(p=0.953)。
关键数值与推荐
- 主要终点为根据标准化肾脏病结局质量倡议(KDOQI)指南定义的从治疗至透析通路功能不良的时间,采用Kaplan-Meier生存曲线评估并以log-rank分析检验显著性。
- 次要终点包括指数血管成形术操作的器械成功、技术成功和临床成功。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: to assess the safety and efficacy of APERTO-Paclitaxel-coated balloon angioplasty versus standard angioplasty for the treatment of dysfunctional hemodialysis shunts and native arteriovenous fistulae. METHODS: consecutive patients with dysfunctional dialysis related to underlying efferent vein stenosis were included and randomized 1:1 to either APERTO-paclitaxel drug-coated balloon (study arm) or standard percutaneous transluminal angioplasty (control arm). Primary endpoint is time from treatment until dialysis access dysfunction according to standardized Kidney Disease Outcomes Quality Initiative (KDOQI)-guidelines and assessed by Kaplan-Meier survival curves and tested for significance with log-rank analysis. Secondary endpoints include device, technical, and clinical success of the index angioplasty procedure. RESULTS: The study included 103 patients (n=51 study-group) with a de novo (n=33) dysfunctional native arteriovenous fistula (n=79) in the forearm (n=60). The majority of included patients were male with a mean age of 69.8 years, presenting with a dysfunctioning autologous arteriovenous fistula in the forearm. Device-related complications did not occur in any of the included patients. Functional hemodialysis access without need for re-intervention at 1 year after index procedure was found in n=10 (19.6%) and n=5 (9.6%) of patients treated with, respectively, paclitaxel drug-coated balloon and percutaneous transluminal angioplasty (p=0.612). A nonsignificant benefit of paclitaxel drug-coated balloon (n=5; 25%) over percutaneous transluminal angioplasty (n=1; 11%) was found (p=0.953) in de novo lesions in autologous fistulas. CONCLUSION: APERTO-paclitaxel drug-coated balloon is a safe balloon catheter to manage dysfunctional hemodialysis access; however, longer period of adequate hemodialysis circuit functioning after endovascular index stenosis treatment, using APERTO-paclitaxel drug-coated balloon versus percutaneous transluminal angioplasty could not be demonstrated.Clinical ImpactAPERTO-paclitaxel drug-coated balloon catheter is a safe device to manage dysfunctional hemodialysis access. Compared to conventional angioplasty balloon, the APERTO drug-coated balloon will not result in longer period of adequate hemodialysis circuit functioning. A non-significant benefit of APERTO drug-coated balloon was found in de novo lesions in autologous fistulas.
引用
- Maleux G, van der Linden E, Heijboer RJJ, et al. Multicenter Randomized Controlled Trial of APERTO-Paclitaxel Drug-Eluting Balloon Angioplasty Versus Standard Percutaneous Transluminal Angioplasty in Dysfunctional Hemodialysis Grafts and Native Fistulae. J Endovasc Ther. 2023. PMID: 38053508. doi:10.1177/15266028231215212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。